{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:20:01Z","timestamp":1792120801330,"version":"4.4.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010665","name":"EU Framework Programme for Research and Innovation Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.ymthe.2025.02.035","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T02:49:43Z","timestamp":1740710983000},"page":"1642-1658","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["CAR-mediated target recognition limits TCR-mediated target recognition of TCR- and CAR-dual-receptor-edited T\u00a0cells"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9507-2530","authenticated-orcid":false,"given":"Tassilo L.A.","family":"Wachsmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7839-9330","authenticated-orcid":false,"given":"Teuntje","family":"Poortvliet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9268-3141","authenticated-orcid":false,"given":"Miranda H.","family":"Meeuwsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis F.G.","family":"Remst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijke F.","family":"Toes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9861-7276","authenticated-orcid":false,"given":"Anne K.","family":"Wouters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate S.","family":"Hagedoorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9819-4813","authenticated-orcid":false,"given":"J.H. Frederik","family":"Falkenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6320-9133","authenticated-orcid":false,"given":"Mirjam H.M.","family":"Heemskerk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.02.035_bib1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ymthe.2025.02.035_bib2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.02.035_bib3","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.02.035_bib4","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T\u00a0cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.02.035_bib5","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.02.035_bib6","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up","volume":"41","author":"Martin","year":"2023","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.02.035_bib7","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.02.035_bib8","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.02.035_bib9","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-019-0737-3","article-title":"Safety and feasibility of anti-CD19 CAR T\u00a0cells with fully human binding domains in patients with B-cell lymphoma","volume":"26","author":"Brudno","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.02.035_bib10","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.02.035_bib11","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T\u00a0cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.02.035_bib12","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.02.035_bib13","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241.x","article-title":"Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival","volume":"158","author":"Sanchez","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ymthe.2025.02.035_bib14","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1182\/blood.2019000050","article-title":"gamma-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T\u00a0cells in multiple myeloma","volume":"134","author":"Pont","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.02.035_bib15","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1038\/ncomms8333","article-title":"gamma-Secretase directly sheds the survival receptor BCMA from plasma cells","volume":"6","author":"Laurent","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.02.035_bib16","article-title":"Both APRIL and antibody-fragment-based CAR T\u00a0cells for myeloma induce BCMA downmodulation by trogocytosis and internalization","volume":"10","author":"Camviel","year":"2022","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2025.02.035_bib17","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1182\/blood-2023-187132","article-title":"Trogocytosis May Attenuate the Efficacy of Anti-BCMA CAR T Cells Administered in Combination with \u03b3-Secretase Inhibitor","volume":"142","author":"Ataca Atilla","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.02.035_bib18","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1182\/blood-2017-04-778423","article-title":"SLAMF7-CAR T\u00a0cells eliminate myeloma and confer selective fratricide of SLAMF7(+) normal lymphocytes","volume":"130","author":"Gogishvili","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.02.035_bib19","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3324\/haematol.2015.137620","article-title":"Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T\u00a0cells for the treatment of multiple myeloma","volume":"101","author":"Drent","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.ymthe.2025.02.035_bib20","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jocit.2014.11.001","article-title":"CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T\u00a0cells for multiple myeloma","volume":"2","author":"Guo","year":"2016","journal-title":"J.\u00a0Cell Immunother."},{"key":"10.1016\/j.ymthe.2025.02.035_bib21","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41571-023-00735-4","article-title":"GPRC5D as a novel immunotherapeutic target in multiple myeloma","volume":"20","author":"Nath","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.02.035_bib22","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-Targeted CAR T\u00a0Cells for Myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.02.035_bib23","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T\u00a0cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.02.035_bib24","doi-asserted-by":"crossref","first-page":"6178","DOI":"10.1182\/bloodadvances.2023010410","article-title":"Combining BCMA-targeting CAR T\u00a0cells with TCR-engineered T-cell therapy to prevent immune escape of multiple myeloma","volume":"7","author":"Wachsmann","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2025.02.035_bib25","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.ymthe.2021.08.010","article-title":"A broad and systematic approach to identify B cell malignancy-targeting TCRs for multi-antigen-based T\u00a0cell therapy","volume":"30","author":"Meeuwsen","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.02.035_bib26","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1182\/blood-2016-09-737536","article-title":"TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1","volume":"129","author":"Jahn","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.02.035_bib27","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1016\/j.jaci.2021.01.027","article-title":"Agammaglobulinemia with normal B-cell numbers in a patient lacking Bob1","volume":"147","author":"Kury","year":"2021","journal-title":"J.\u00a0Allergy Clin. Immunol."},{"key":"10.1016\/j.ymthe.2025.02.035_bib28","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1002\/eji.1830261255","article-title":"B lymphocytes are impaired in mice lacking the transcriptional co-activator Bob1\/OCA-B\/OBF1","volume":"26","author":"Nielsen","year":"1996","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ymthe.2025.02.035_bib29","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/eji.202149333","article-title":"BOB.1\/OBF.1 is required during B-cell ontogeny for B-cell differentiation and germinal center function","volume":"52","author":"Betzler","year":"2022","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ymthe.2025.02.035_bib30","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/s43018-023-00550-x","article-title":"Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias","volume":"4","author":"de Matos Simoes","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ymthe.2025.02.035_bib31","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1182\/blood-2020-142580","article-title":"POU2AF1 As a Master Regulator of Oncogenic Transcription Factor Networks in Myeloma","volume":"136","author":"De Matos Simoes","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.02.035_bib32","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1182\/blood-2021-152121","article-title":"B Cell Transcriptional Coactivator POU2AF1 (BOB-1) Is an Early Transcription Factor Modulating the Protein Synthesis and Ribosomal Biogenesis in Multiple Myeloma: With Therapeutic Implication","volume":"138","author":"Chyra","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.02.035_bib33","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1158\/1535-7163.MCT-17-1097","article-title":"Strategies to Address Chimeric Antigen Receptor Tonic Signaling","volume":"17","author":"Ajina","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ymthe.2025.02.035_bib34","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1158\/2326-6066.CIR-14-0186","article-title":"Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T\u00a0cells","volume":"3","author":"Frigault","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2025.02.035_bib36","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nm.3910","article-title":"NY-ESO-1-specific TCR-engineered T\u00a0cells mediate sustained antigen-specific antitumor effects in myeloma","volume":"21","author":"Rapoport","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.02.035_bib35","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1158\/1535-7163.MCT-21-0552","article-title":"Preclinical Efficacy of BCMA-Directed CAR T Cells Incorporating a Novel D Domain Antigen Recognition Domain","volume":"21","author":"Buonato","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ymthe.2025.02.035_bib37","doi-asserted-by":"crossref","first-page":"6116","DOI":"10.4049\/jimmunol.180.9.6116","article-title":"Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T\u00a0cell functions","volume":"180","author":"Robbins","year":"2008","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2025.02.035_bib38","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.ymthe.2018.06.012","article-title":"CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma","volume":"26","author":"Bluhm","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.02.035_bib39","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1126\/science.1546328","article-title":"Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry","volume":"255","author":"Hunt","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.02.035_bib40","doi-asserted-by":"crossref","first-page":"E2068","DOI":"10.1073\/pnas.1716266115","article-title":"Chimeric antigen receptor T\u00a0cells form nonclassical and potent immune synapses driving rapid cytotoxicity","volume":"115","author":"Davenport","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.02.035_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1110482","article-title":"CAR and TCR form individual signaling synapses and do not cross-activate, however, can co-operate in T\u00a0cell activation","volume":"14","author":"Barden","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.02.035_bib42","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/ni863","article-title":"TCRs with high affinity for foreign pMHC show self-reactivity","volume":"4","author":"Holler","year":"2003","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2025.02.035_bib43","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","article-title":"Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy","volume":"36","author":"Morgan","year":"2013","journal-title":"J.\u00a0Immunother."},{"key":"10.1016\/j.ymthe.2025.02.035_bib44","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T\u00a0cells in myeloma and melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.02.035_bib45","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41467-017-00296-y","article-title":"Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing","volume":"8","author":"Rasche","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.02.035_bib46","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T\u00a0cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.02.035_bib47","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1038\/s41467-020-16160-5","article-title":"Systematically optimized BCMA\/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma","volume":"11","author":"Zah","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.02.035_bib48","doi-asserted-by":"crossref","first-page":"7509","DOI":"10.1038\/s41467-023-43416-7","article-title":"Anti-TACI single and dual-targeting CAR T\u00a0cells overcome BCMA antigen loss in multiple myeloma","volume":"14","author":"Larson","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.02.035_bib49","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1172\/JCI87366","article-title":"Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies","volume":"126","author":"Ruella","year":"2016","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.02.035_bib50","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.omto.2018.10.006","article-title":"Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22","volume":"11","author":"Qin","year":"2018","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.ymthe.2025.02.035_bib51","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","article-title":"Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma","volume":"1","author":"Fernandez de Larrea","year":"2020","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.ymthe.2025.02.035_bib52","doi-asserted-by":"crossref","first-page":"696","DOI":"10.3390\/cancers11050696","article-title":"Arming T Cells with a gp100-Specific TCR and a CSPG4-Specific CAR Using Combined DNA- and RNA-Based Receptor Transfer","volume":"11","author":"Simon","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ymthe.2025.02.035_bib53","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/exd.13095","article-title":"Combining a chimeric antigen receptor and a conventional T-cell receptor to generate T\u00a0cells expressing two additional receptors (TETARs) for a multi-hit immunotherapy of melanoma","volume":"25","author":"Uslu","year":"2016","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.ymthe.2025.02.035_bib54","article-title":"CAR'TCR-T cells co-expressing CD33-CAR and dNPM1-TCR as superior dual-targeting approach for AML treatment. Molecular therapy","volume":"32","author":"Teppert","year":"2024","journal-title":"Oncology"},{"key":"10.1016\/j.ymthe.2025.02.035_bib55","article-title":"Generating CAR T\u00a0cells from\u00a0tumor-infiltrating lymphocytes","volume":"9","author":"Mills","year":"2021","journal-title":"Ther. Adv. Vaccin. Immunother."},{"key":"10.1016\/j.ymthe.2025.02.035_bib56","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030648","article-title":"Treatment with Anti-HER2 Chimeric Antigen Receptor Tumor-Infiltrating Lymphocytes (CAR-TILs) Is Safe and Associated with Antitumor Efficacy in Mice and Companion Dogs","volume":"15","author":"Forsberg","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ymthe.2025.02.035_bib57","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/nm.4258","article-title":"Donor CD19 CAR T\u00a0cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity","volume":"23","author":"Ghosh","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.02.035_bib58","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/protein\/6.8.989","article-title":"An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability","volume":"6","author":"Whitlow","year":"1993","journal-title":"Protein Eng."},{"key":"10.1016\/j.ymthe.2025.02.035_bib59","series-title":"Natural Killer Cell Protocols: Cellular and Molecular Methods","first-page":"89","article-title":"Natural Killer Cell Conjugate Assay Using Two-Color Flow Cytometry","author":"Burshtyn","year":"2010"},{"key":"10.1016\/j.ymthe.2025.02.035_bib60","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/09537104.2020.1797323","article-title":"Isolation of murine bone marrow by centrifugation or flushing for the analysis of hematopoietic cells - a comparative study","volume":"32","author":"Heib","year":"2021","journal-title":"Platelets"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162500125X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162500125X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T20:44:46Z","timestamp":1751575486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152500162500125X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S152500162500125X"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.02.035","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR-mediated target recognition limits TCR-mediated target recognition of TCR- and CAR-dual-receptor-edited T\u00a0cells","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.02.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}